Morgan Stanley Reaffirms Equal Weight Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD)
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report)‘s stock had its “equal weight” rating reaffirmed by investment analysts at Morgan Stanley in a report issued on Friday,Benzinga reports. They currently have a $20.00 target price on the biopharmaceutical company’s stock. Morgan Stanley’s price objective points to a potential upside of 13.90% from the stock’s previous close. […]
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report)‘s stock had its “equal weight” rating reaffirmed by investment analysts at Morgan Stanley in a report issued on Friday,Benzinga reports. They currently have a $20.00 target price on the biopharmaceutical company’s stock. Morgan Stanley’s price objective points to a potential upside of 13.90% from the stock’s previous close. […]
